-
Bayesian modelling of response to therapy and drug-sensitivity in acute lymphoblastic leukemia
Authors:
Andrea Cremaschi,
Wenjian Yang,
Maria De Iorio,
William E. Evans,
Jun J. Yang,
Gary L. Rosner
Abstract:
Acute lymphoblastic leukemia (ALL) is a heterogeneous hematologic malignancy involving the abnormal proliferation of immature lymphocytes, accounting for most pediatric cancer cases. ALL management in children has seen great improvement in the last decades thanks to better understanding of the disease leading to improved treatment strategies evidenced through clinical trials. Commonly a first cour…
▽ More
Acute lymphoblastic leukemia (ALL) is a heterogeneous hematologic malignancy involving the abnormal proliferation of immature lymphocytes, accounting for most pediatric cancer cases. ALL management in children has seen great improvement in the last decades thanks to better understanding of the disease leading to improved treatment strategies evidenced through clinical trials. Commonly a first course of chemotherapy (induction phase) is administered, followed by treatment with a combination of anti-leukemia drugs. A measure of the efficacy early in the course of therapy is minimal residual disease (MRD). MRD quantifies residual tumor cells and indicates the effectiveness of the treatment over the course of therapy. MRD positivity is defined for values of MRD greater than 0.01%, yielding left-censored observations. We propose a Bayesian model to study the relationship between patient features and MRD observed at two time points during the induction phase. Specifically, we model the observed MRD values via an auto-regressive model, accounting for left-censoring of the data and for the fact that some patients are already in remission after the induction phase. Patient characteristics are included in the model via linear regression terms. In particular, patient-specific drug sensitivity based on ex-vivo assays of patient samples is exploited to identify groups of subjects with similar profiles. We include this information as a covariate in the model for MRD. We adopt horseshoe priors for the regression coefficients to perform variable selection to identify important covariates. We fit the proposed approach to data from three prospective pediatric ALL clinical trials carried out at the St. Jude Children's Research Hospital. Our results highlight that drug sensitivity profiles and leukemic subtypes play an important role in the response to induction therapy as measured by serial MRD measures.
△ Less
Submitted 7 November, 2023;
originally announced November 2023.
-
Bayesian Inference for Latent Chain Graphs
Authors:
Deng Lu,
Maria De Iorio,
Ajay Jasra,
Gary L. Rosner
Abstract:
In this article we consider Bayesian inference for partially observed Andersson-Madigan-Perlman (AMP) Gaussian chain graph (CG) models. Such models are of particular interest in applications such as biological networks and financial time series. The model itself features a variety of constraints which make both prior modeling and computational inference challenging. We develop a framework for the…
▽ More
In this article we consider Bayesian inference for partially observed Andersson-Madigan-Perlman (AMP) Gaussian chain graph (CG) models. Such models are of particular interest in applications such as biological networks and financial time series. The model itself features a variety of constraints which make both prior modeling and computational inference challenging. We develop a framework for the aforementioned challenges, using a sequential Monte Carlo (SMC) method for statistical inference. Our approach is illustrated on both simulated data as well as real case studies from university graduation rates and a pharmacokinetics study.
△ Less
Submitted 12 August, 2019;
originally announced August 2019.
-
Discovering Interactions Using Covariate Informed Random Partition Models
Authors:
Garritt L. Page,
Fernando A. Quintana,
Gary L. Rosner
Abstract:
Combination chemotherapy treatment regimens created for patients diagnosed with childhood acute lymphoblastic leukemia have had great success in improving cure rates. Unfortunately, patients prescribed these types of treatment regimens have displayed susceptibility to the onset of osteonecrosis. Some have suggested that this is due to pharmacokinetic interaction between two agents in the treatment…
▽ More
Combination chemotherapy treatment regimens created for patients diagnosed with childhood acute lymphoblastic leukemia have had great success in improving cure rates. Unfortunately, patients prescribed these types of treatment regimens have displayed susceptibility to the onset of osteonecrosis. Some have suggested that this is due to pharmacokinetic interaction between two agents in the treatment regimen (asparaginase and dexamethasone) and other physiological variables. Determining which physiological variables to consider when searching for interactions in scenarios like these, minus a priori guidance, has proved to be a challenging problem, particularly if interactions influence the response distribution in ways beyond shifts in expectation or dispersion only. In this paper we propose an exploratory technique that is able to discover associations between covariates and responses in a very general way. The procedure connects covariates to responses very flexibly through dependent random partition prior distributions, and then employs machine learning techniques to highlight potential associations found in each cluster. We provide a simulation study to show utility and apply the method to data produced from a study dedicated to learning which physiological predictors influence severity of osteonecrosis multiplicatively.
△ Less
Submitted 3 August, 2020; v1 submitted 28 September, 2018;
originally announced October 2018.
-
Individualized Treatment Effects with Censored Data via Fully Nonparametric Bayesian Accelerated Failure Time Models
Authors:
Nicholas C. Henderson,
Thomas A. Louis,
Gary L. Rosner,
Ravi Varadhan
Abstract:
Individuals often respond differently to identical treatments, and characterizing such variability in treatment response is an important aim in the practice of personalized medicine. In this article, we describe a non-parametric accelerated failure time model that can be used to analyze heterogeneous treatment effects (HTE) when patient outcomes are time-to-event. By utilizing Bayesian additive re…
▽ More
Individuals often respond differently to identical treatments, and characterizing such variability in treatment response is an important aim in the practice of personalized medicine. In this article, we describe a non-parametric accelerated failure time model that can be used to analyze heterogeneous treatment effects (HTE) when patient outcomes are time-to-event. By utilizing Bayesian additive regression trees and a mean-constrained Dirichlet process mixture model, our approach offers a flexible model for the regression function while placing few restrictions on the baseline hazard. Our non-parametric method leads to natural estimates of individual treatment effect and has the flexibility to address many major goals of HTE assessment. Moreover, our method requires little user input in terms of tuning parameter selection or subgroup specification. We illustrate the merits of our proposed approach with a detailed analysis of two large clinical trials for the prevention and treatment of congestive heart failure using an angiotensin-converting enzyme inhibitor. The analysis revealed considerable evidence for the presence of HTE in both trials as demonstrated by substantial estimated variation in treatment effect and by high proportions of patients exhibiting strong evidence of having treatment effects which differ from the overall treatment effect.
△ Less
Submitted 20 June, 2017;
originally announced June 2017.
